| Old Articles: <Older 21751-21760 Newer> |
|---|
 |
The Motley Fool
March 23, 2007
Rick Aristotle Munarriz |
3M Plays Catch-Up Despite volatility, the industrial conglomerate could still be a good long-term option.   |
The Motley Fool
March 23, 2007
Anders Bylund |
In the Shade of the Palm: Fool by Numbers The gadget maker released third-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
March 23, 2007
David Lee Smith |
KB Home Is OK KB Home, while clearly not out of the woods, is experiencing the sort of results that could lead to improved fortunes. Investors, take note. |
The Motley Fool
March 23, 2007
Tim Beyers |
Joe Nacchio Is Guilty ... of Being a Moron The former Qwest CEO's poor management destroyed lives. Nacchio could have easily adjusted guidance so as to make the super-secret federal contracts a pleasant surprise for the Street if they ever came through. |
The Motley Fool
March 23, 2007
Dale Baker |
Transfield: Now That's What I Call Global Service Australian multinational Transfield Services operates the infrastructure that keeps the worldwide economic engine running. Investors, take note. |
The Motley Fool
March 23, 2007
Rick Aristotle Munarriz |
Activision's Monster Plan Promoter Live Nation is teaming up with Activision to release the first Monster Jam game later this year. Investors, take note. |
The Motley Fool
March 23, 2007
Anders Bylund |
Pick a Market, Sigma Claiming a 75% market share is great, but can chipmaker Sigma Designs back it up? Investors, take note. |
BusinessWeek
April 2, 2007
Gene G. Marcial |
Bubbling Up At Dressler With infrastructure spending in the oil-and-gas industry starting to rise, Dresser-Rand Group, a leading maker of large compressors, turbines, and control systems, is catching the eye of investors. |
BusinessWeek
April 2, 2007
Gene G. Marcial |
Advanced Life Sciences Is Advancing On Anthrax Investors who stuck with Advanced Life Sciences even after it delayed completion of Phase 3 clinical trials on cethromycin felt rewarded when the Food & Drug Administration granted it "Orphan Drug" designation. |
BusinessWeek
April 2, 2007
Gene G. Marcial |
A Fresh Charge For Ultralife Batteries? Ultralife batteries posted record sales in the fourth quarter, but it's still in the red, partly because of a recent acquisition. |
| <Older 21751-21760 Newer> Return to current articles. |
